Understanding the Stages of Multiple System Atrophy (MSA)

Understanding the Stages of Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several brain regions, resulting in symptoms related to movement, autonomic function, and sleep.
Here's how the progression of MSA can be understood:

Initial (Early) Stage:
  • Symptoms include autonomic dysfunctions like orthostatic hypotension (dizziness or fainting when standing), constipation, urinary problems (incontinence or retention), and sexual dysfunction.
  • Mild parkinsonian symptoms might start appearing, including rigidity and bradykinesia (slow movement).
  • For cerebellar type (MSA-C), balance issues and uncoordinated movements might be evident.
  • Daily activities are still manageable with some adaptations, but diagnosis can be tricky due to similarity with other conditions.

Intermediate Stage:
  • Autonomic symptoms become more severe, with more frequent issues with blood pressure possibly needing treatment.
  • Motor symptoms progress, with increased rigidity, slower movements, and possible tremors. Speech and swallowing difficulties emerge.
  • Sleep disorders like REM sleep behavior disorder become noticeable or worsen.
  • Mobility might require aids like canes or walkers. Daily life becomes more challenging, with a higher dependency on caregivers.

Advanced (Late) Stage:
  • Autonomic failure is profound, with severe blood pressure fluctuations, temperature regulation issues, and significant urinary and bowel problems.
  • Motor impairment is extreme; individuals might be wheelchair-bound or bedridden with a loss of voluntary movement.
  • Speech is severely impaired, making it difficult or impossible to communicate without aids.
  • Cognitive or psychiatric symptoms might develop.
  • The focus shifts to comfort, palliative care, and end-of-life planning.

Note on Staging:
  • MSA's progression isn't universally staged like some diseases, with variability among individuals.
  • Life expectancy post-diagnosis averages 6 to 10 years, influenced by various factors including MSA subtype and overall health.

Conclusion:
  • Recognizing these stages aids in planning care, setting realistic expectations, and managing the disease's effects.
  • Early diagnosis and symptom management can improve quality of life.
  • Research continues to aim for better symptom control and possibly slowing or stopping disease progression.
  • Awareness and education about MSA are crucial for enhanced patient care and research advancement.
    Back to blog

    Leave a public comment:

    Please note, comments need to be approved before they are published.

    • HOPE by Bhavna

      HOPE by Bhavna

      Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

      HOPE by Bhavna

      Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

    • Active Neurodegenerative Disease Clinical Trials (PSP, MSA, DLB, CBS, Parkinsonian Syndromes)

      Active Neurodegenerative Disease Clinical Trial...

      Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 โ€“ PROSPERPurpose:ย To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

      Active Neurodegenerative Disease Clinical Trial...

      Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 โ€“ PROSPERPurpose:ย To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

    • Recruiting participants for a groundbreaking study: โ€œAssessing Cognitive Trajectories in Progressive Supranuclear Palsy Using Remote Computerized Reaction Time Tasks.โ€

      Recruiting participants for a groundbreaking st...

      Melbourne, Victoria โ€“ September 9, 2025 โ€“ The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

      Recruiting participants for a groundbreaking st...

      Melbourne, Victoria โ€“ September 9, 2025 โ€“ The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

    • WAITING By Bhavna

      WAITING By Bhavna

      For four years, she had lived with the unraveling of a rare brain disease. Progressive Supranuclear Palsy. Each step making her more dependent. Each fall more brutal. And each word...

      2 comments

      WAITING By Bhavna

      For four years, she had lived with the unraveling of a rare brain disease. Progressive Supranuclear Palsy. Each step making her more dependent. Each fall more brutal. And each word...

      2 comments
    1 of 4